Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial.

Parazzini F, Fedele L, Busacca M, Falsetti L, Pellegrini S, Venturini PL, Stella M

American journal of obstetrics and gynecology1 Nov 1994Cited by 76 (Europe PMC)

PMID7977520DOI10.1016/0002-9378(94)90133-3PepBankPUB-07977520

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with advanced endometriosis, pregnancy within 1 year occurred in seven of 36 nafarelin patients (19%) versus seven of 39 placebo patients (18%).
In plain wordsIn women with advanced endometriosis, pregnancy occurred in 19% with nafarelin versus 18% with placebo within 1 year.
Peptide
Nafarelin
Outcome
IncreasePregnancy within 1 year
Study
n = 75
Comparator
Placebo nasal spray
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 micrograms/day · nasal · 3 monthsAs given in this study (human).
Measurements
Pregnancies within 1 year
7 patients (of 36)
nafarelin
Pregnancy proportion within 1 year
19%
nafarelin
Pregnancies within 1 year
7 patients (of 39)
placebo
Pregnancy proportion within 1 year
18%
placebo
Source sentences
Summary
Within 1 year from randomization, of the 36 women allocated to nafarelin and the 39 allocated to placebo, seven (19%) and seven (18%), respectively, became pregnant.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients were assigned according to a randomization list to nasal nafarelin, 400 micrograms/day (36 subjects) or placebo nasal spray (39 subjects) for 3 months.
Summary · context
Pelvic pain was assessed before first surgery and at the 12-month follow-up visit in women with pelvic pain by means of a multidimensional score system and a 10-point linear pain scale.
Report a problemFND-0797752003
02HumanRandomized controlled trialEfficacy outcome
In women with advanced endometriosis, multidimensional pain scores fell by 3.6 with nafarelin versus 4.0 with placebo, without significant difference.
In plain wordsIn women with advanced endometriosis, nafarelin and placebo produced similar reductions in multidimensional pain scores.
Peptide
Nafarelin
Outcome
No significant changeMultidimensional pelvic pain score
Study
n: not reported in source
Comparator
Placebo nasal spray
Outcome group
Pain · Reproductive and sexual health
Studied dose
400 micrograms/day · nasal · 3 monthsAs given in this study (human).
Measurements
Mean reduction in multidimensional pain score
3.6 score points
nafarelin
Mean reduction in multidimensional pain score
4 score points
placebo
Source sentences
Summary
The mean reduction of the multidimensional score was 3.6 and 4.0, respectively, in women allocated to nafarelin and placebo and of the 10-point linear scale scores was 7.0 and 6.9.
3 context sentences(design, population, supporting numbers)
Summary · context
These differences were not statistically significant.
Summary · context
Patients were assigned according to a randomization list to nasal nafarelin, 400 micrograms/day (36 subjects) or placebo nasal spray (39 subjects) for 3 months.
Summary · context
Pelvic pain was assessed before first surgery and at the 12-month follow-up visit in women with pelvic pain by means of a multidimensional score system and a 10-point linear pain scale.
Report a problemFND-0797752001
03HumanRandomized controlled trialEfficacy outcome
In women with advanced endometriosis, linear pain scores fell by 7.0 with nafarelin versus 6.9 with placebo, without significant difference.
In plain wordsIn women with advanced endometriosis, nafarelin and placebo produced similar reductions in linear pain scores.
Peptide
Nafarelin
Outcome
No significant changeLinear pelvic pain score
Study
n: not reported in source
Comparator
Placebo nasal spray
Outcome group
Pain · Reproductive and sexual health
Studied dose
400 micrograms/day · nasal · 3 monthsAs given in this study (human).
Measurements
Mean reduction in 10-point linear pain scale score
7 points on 10-point scale
nafarelin
Mean reduction in 10-point linear pain scale score
6.9 points on 10-point scale
placebo
Source sentences
Summary
The mean reduction of the multidimensional score was 3.6 and 4.0, respectively, in women allocated to nafarelin and placebo and of the 10-point linear scale scores was 7.0 and 6.9.
3 context sentences(design, population, supporting numbers)
Summary · context
These differences were not statistically significant.
Summary · context
Patients were assigned according to a randomization list to nasal nafarelin, 400 micrograms/day (36 subjects) or placebo nasal spray (39 subjects) for 3 months.
Summary · context
Pelvic pain was assessed before first surgery and at the 12-month follow-up visit in women with pelvic pain by means of a multidimensional score system and a 10-point linear pain scale.
Report a problemFND-0797752002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.